生物标志物定义的临床前阿尔茨海默病中的线索记忆下降
研究在276名临床正常老年人中,探讨PET显示β-淀粉样蛋白(Aβ)负担升高者是否可出现线索回忆下降。平均随访3.6±1.2年,Aβ+者总回忆下降(≤46/48)风险为Aβ-者的3.55倍(95%CI=1.77-7.12),且下降者海马体积更小、进展为临床痴呆评定量表0.5的风险更高。
要点
- Aβ+临床正常老年人线索记忆下降风险约为Aβ-者的3.55倍。
- 线索记忆下降者海马体积更小,早期功能下降风险更高。
- 线索记忆下降或有助于识别短期临床进展风险最高的Aβ+个体。
核心结论
- 临床正常老年人中线索记忆下降可能特别提示Aβ相关的临床前AD阶段衰退,并有助于识别短期临床进展风险最高的Aβ+个体。
研究设计与样本
- 纳入276名临床痴呆评定量表为0的临床正常老年人,基线行PET评估Aβ状态及MRI,并每年进行神经心理学测试。
- 采用Cox比例风险模型评估线索记忆下降与神经影像、功能状态、年龄、性别和教育的关联。
- 平均随访3.6±1.2年,平均简易精神状态检查评分为29±1.06。
主要发现
- 仅19%参与者在第3年时总回忆评分≤46/48,线索记忆下降并不常见。
- Aβ+参与者出现总回忆下降(≤46/48)的可能性是Aβ-者的3.55倍(95%CI=1.77-7.12)。
- 评分为≤46/48的Aβ+参与者海马体积更小(t=3.37,p=0.001)。
- 评分为≤46/48的Aβ+参与者进展为总体临床痴呆评定量表0.5的风险更高(χ2=14.30,p<0.001)。
关键数值与推荐
- 线索记忆下降定义为自由和线索选择性提醒测验总分下降1、2、3或4分。
- 总回忆下降采用≤46/48(满分48)作为判定标准。
临床怎么用
- 对临床正常的Aβ+老年人可关注线索记忆测验表现,辅助识别短期临床进展风险较高者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether a decline in cued recall is observable in the preclinical stage of Alzheimer disease (AD) in clinically normal older adults with elevated β-amyloid (Aβ) burden on PET imaging. METHODS: Clinically normal older adults underwent baseline neuroimaging (PET to assess Aβ+/- status and MRI) and annual neuropsychological testing. Cox proportional hazards models were used to assess the relative risk of cued memory decline (drop of 1, 2, 3, or 4 points on the total score of the Free and Cued Selective Reminding Test) in relation to neuroimaging measures, functional status, age, sex, and education. RESULTS: A total of 276 older adults (Clinical Dementia Rating = 0, mean Mini-Mental State Examination score = 29 ± 1.06) were followed up for a mean of 3.6 ± 1.2 years. Despite the infrequency of cued memory decline (only 19% of participants scored ≤46/48 in total recall by year 3), Aβ+ participants were 3.55 times (95% confidence interval = 1.77-7.12) more likely to exhibit decline in total recall (≤46/48) compared with their Aβ- peers. Furthermore, Aβ+ participants who scored ≤46/48 had smaller hippocampal volumes (t = 3.37, p = 0.001) and evidence of early functional decline, i.e., greater risk of progression to global Clinical Dementia Rating of 0.5 (χ2 = 14.30, p < 0.001), compared with their Aβ+ peers with intact total recall. CONCLUSIONS: Cued memory decline in healthy older adults may be particularly indicative of Aβ-related decline during the preclinical stage of AD and useful for identifying Aβ+ clinically normal individuals at greatest risk of short-term clinical progression.
引用
- Papp KV, Rentz DM, Mormino EC, et al. Cued memory decline in biomarker-defined preclinical Alzheimer disease. Neurology. 2017. PMID: 28283594. doi:10.1212/WNL.0000000000003812
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。